Identification of potential drugs for diffuse large b-cell lymphoma based on bioinformatics and Connectivity Map database

Diffuse large B-cell lymphoma (DLBCL) is the most main subtype in non-Hodgkin lymphoma. After chemotherapy, about 30% of patients with DLBCL develop resistance and relapse. This study was to identify potential therapeutic drugs for DLBCL using the bioinformatics method. The differentially expressed genes (DEGs) between DLBCL and non-cancer samples were downloaded from the Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO). Gene ontology enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of DEGs were analyzed using the Database for Annotation, Visualization, and Integrated Discovery. The R software package (SubpathwayMiner) was used to perform pathway analysis on DEGs affected by drugs found in the Connectivity Map (CMap) database. Protein–protein interaction (PPI) networks of DEGs were constructed using the Search Tool for the Retrieval of Interacting Genes online database and Cytoscape software. In order to identify potential novel drugs for DLBCL, the DLBCL-related pathways and drug-affected pathways were integrated. The results showed that 1927 DEGs were identified from TCGA and GEO. We found 54 significant pathways of DLBCL using KEGG pathway analysis. By integrating pathways, we identified five overlapping pathways and 47 drugs that affected these pathways. The PPI network analysis results showed that the CDK2 is closely associated with three overlapping pathways (cell cycle, p53 signaling pathway, and small cell lung cancer). The further literature verification results showed that etoposide, rinotecan, methotrexate, resveratrol, and irinotecan have been used as classic clinical drugs for DLBCL. Anisomycin, naproxen, gossypol, vorinostat, emetine, mycophenolic acid and daunorubicin also act on DLBCL. It was found through bioinformatics analysis that paclitaxel in the drug-pathway network can be used as a potential novel drug for DLBCL.     

Subcutaneous Dissemination from an Orbital Diffuse Large B Cell Lymphoma

Secondary cutaneous dissemination from an orbital diffuse large B cell lymphoma has not been described before. The authors report an unusual case of anaplastic variant of diffuse large B cell lymphoma which primarily presented in the orbit and during the course of disease had subcutaneous dissemination.     

护理干预对弥漫性轴索损伤患者预后的影响

目的 探讨护理干预对弥漫性轴索损伤患者预后的影响.方法 将40例弥漫性轴索损伤的患者分为观察组和对照组,对照组采用常规护理,观察组采用预见性护理,比较两组的护理效果.结果 观察组的昏迷时间、并发症的发生率、COS(预后)情况显著优于对照组(P＜0.05).且观察组的生活能力及神经缺损程度方面显著优于对照组(P＜0.05).结论 预见性护理有利于减少弥漫性轴索损伤患者的并发症,改善患者的预后,提高生活质量.     

结直肠损伤

近年来结直肠损伤的救治水平有了明显进步,但仍存在并发症发生率高、腹膜外结直肠损伤漏诊率高、转流造口手术率高等问题。本文介绍了结直肠损伤的2种分类方法:穿透伤和钝性伤,毁损伤和非毁损伤。在分析结直肠损伤漏诊有关因素的基础上,提出了诊断策略和剖腹术中探查要点,全面阐述了结肠和腹膜内段直肠、腹膜外段直肠的手术策略和手术方式。     

硫酸镁联合尼莫地平治疗弥漫性轴索损伤的临床分析

目的 研究弥漫性轴索损伤(DAI)患者的血清镁离子浓度以及联合尼莫地平早期给予镁离子治疗对其预后的影响. 方法 将南方医科大学珠江医院神经外科自2006年9月至2010年6月收治的99例DAI患者按随机数字表法分为2组,入院时均检测血清镁离子浓度,均予尼莫地平持续静脉注射,连续使用1周.另治疗组给予250g/L硫酸镁静脉滴注,连续使用3d;对照组不使用硫酸镁.结合随访情况,分析患者预后与入院时镁离子浓度及与硫酸镁治疗的关系. 结果 2组患者间病死率比较差异无统计学意义(P＜0.05),治疗组恢复良好率及轻残率均明显高于对照组,差异有统计学意义(P＜0.05).2组患者入院时血清镁离子浓度均对格拉斯哥预后分级评分(GOS)无明显影响. 结论 入院时血清镁离子水平不能影响患者的预后.对比单独使用尼莫地平,伤后早期联合应用250 g/L硫酸镁持续静脉滴注,虽不能有效降低患者死亡率,但可降低重残率,改善患者的预后和生存质量.     

Genomic Analysis Reveals Distinct Subtypes in Two Rare Cases of Primary Ovarian Lymphoma

Primary (localized) non-Hodgkin lymphoma (NHL) of the ovary is extremely rare; only a few cases have been reported in the literature. We report two cases of primary ovarian lymphoma (POL), one involving bilateral ovaries in a 15-year-old girl and other involving one ovary in a 5-year-old girl. This report describes detailed clinical, histopathological, and imaging findings, along with the review of literature of primary diffuse large B-cell lymphoma (DLBCL) arising from an ovary. In addition, we describe findings of targeted capture panel sequencing on both tumors and identify the major genetic mutations that are recurrently mutated in pan-cancers. Compared to the genomic mutation features of major subtypes of DLBCL, we distinguish that each POL belongs to distinctive subtypes, GCB (germinal center B-cell subtype) DLBCL and ABC (activated B-cell subtype) DLBCL, respectively. The findings from the genomic analysis may help to understand the pathogenesis of POL and to guide potential targeted therapy in the future.     

Silicone pneumonitis,diffuse alveolar hemorrhage and acute respiratory distress syndrome from gluteal silicone injections

Fatal complications from illegal cosmetic injection of nonmedical-grade liquid silicone (polydimethylsiloxane) by unlicensed providers are becoming more common. Silicone embolization syndrome (SES) can rapidly progress to pneumonitis and diffuse alveolar hemorrhage. Prompt and aggressive management with high-dose steroids and lung-protective ventilation strategies to minimize acute respiratory distress syndrome (ARDS) can be lifesaving. We present the case of a patient presenting with abdominal pain and shortness of breath who quickly developed respiratory failure. The patient recently had received bilateral gluteal silicone injections from an unlicensed provider.     

Large Lipomatous Hypertrophy of the Interventricular Septum

We present the case of a 58-year-old woman who had large lipomatous hypertrophy of the interventricular septum, a condition that is reported very infrequently. Preoperative cardiac magnetic resonance images revealed an inhomogeneous, infiltrating mass that was suppressed in fat-suppression mode. The extensive mass was causing right ventricular dysfunction, so we excised it through a right ventricular approach. The findings on histologic analysis of the mass were consistent with lipomatous hypertrophy. The patient died of septic shock on the 28th postoperative day. In addition to the patient''s case, we discuss the characteristics and diagnosis of this rare entity.